Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

doi:10.1200/JCO.22.01763

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jan 2023

Atkins Michael B, Lee Sandra J, Chmielowski Bartosz, Tarhini Ahmad A, Cohen Gary I, Truong Thach-Giao, Moon Helen H, Davar Diwakar, O'Rourke Mark, Stephenson Joseph J, Curti Brendan D, Urba Walter J, Brell Joanna M, Funchain Pauline, Kendra Kari L, Ikeguchi Alexandra P, Jaslowski Anthony, Bane Charles L, Taylor Mark A, Bajaj Madhuri, Conry Robert M, Ellis Robert J, Logan Theodore F, Laudi Noel, Sosman Jeffrey A, Crockett David G, Pecora Andrew L, Okazaki Ian J, Reganti Sowjanya, Chandra Sunandana, Guild Samantha, Chen Helen X, Streicher Howard Z, Wolchok Jedd D, Ribas Antoni, Kirkwood John M

Abstract excerpt

PURPOSE: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Ipilimumab

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Nivolumab

Share to Oximes

Share to Pyridones

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36166727
DOI: 10.1200/JCO.22.01763
PMCID: PMC9839305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.PMID 36166727Read ↗

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Semantic proximity Read ↗

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanomaSemantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.